CRISIL upgrades rating of Alembic Pharma’s long-term bank facilities

24 Jul 2017 Evaluate

Credit rating agency, CRISIL has upgraded the rating of long-term bank facilities of Alembic Pharmaceuticals to ‘AA+/Stable’ from ‘AA/Positive’ worth Rs 315 crore limit of fund/non-fund based facilities.

Moreover, the rating agency has reaffirmed the rating of the company's short-term debt including Commercial Paper to ‘A1+’ worth Rs 200 crore.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×